These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31378670)

  • 1. Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States.
    Frow EK; Brafman DA; Muldoon A; Krum L; Williams P; Becker B; Nelson JP; Pritchett A
    Stem Cell Reports; 2019 Aug; 13(2):247-253. PubMed ID: 31378670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.
    Knoepfler PS; Turner LG
    Regen Med; 2018 Jan; 13(1):19-27. PubMed ID: 29327974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weighing up the evidence used by direct-to-consumer stem cell businesses.
    Cook M; Richey A; Brafman DA; Frow EK
    Stem Cell Reports; 2021 Dec; 16(12):2852-2860. PubMed ID: 34767748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration's enforcement discretion era.
    Turner L; Wang JC; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Sahrai V
    Cytotherapy; 2024 Apr; 26(4):393-403. PubMed ID: 38340106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. US stem cell clinics, patient safety, and the FDA.
    Turner L
    Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing "Cell Therapy" Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States.
    Nirwan RS; Albini TA; Sridhar J; Flynn HW; Kuriyan AE
    Ophthalmology; 2019 Oct; 126(10):1350-1355. PubMed ID: 30904542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study Shows Businesses Selling Unapproved Stem Cell Treatments Have Turned to Long COVID.
    Eastman Q
    JAMA; 2023 Dec; 330(24):2326-2327. PubMed ID: 38019493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
    Turner L; Knoepfler P
    Cell Stem Cell; 2016 Aug; 19(2):154-157. PubMed ID: 27374789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Online seminars as an information source for direct-to-consumer stem cell therapy.
    Hassoun M; Golub S; Greenfield S; Grill JD; Cummings BJ
    Regen Med; 2022 Feb; 17(2):81-90. PubMed ID: 34949108
    [No Abstract]   [Full Text] [Related]  

  • 12. Uncovering the gray zone: mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes.
    Asadpour A; Yahaya BH; Bicknell K; Cottrell GS; Widera D
    Stem Cell Res Ther; 2023 May; 14(1):111. PubMed ID: 37138298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA Draft Guidance Documents.
    Turner LG
    Mayo Clin Proc; 2015 May; 90(5):567-71. PubMed ID: 25939934
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies.
    Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC
    Regen Med; 2023 Nov; 18(11):857-868. PubMed ID: 37867326
    [No Abstract]   [Full Text] [Related]  

  • 16. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions.
    Turner LG
    Regen Med; 2015 May; 10(4):397-402. PubMed ID: 26022761
    [No Abstract]   [Full Text] [Related]  

  • 17. Identity and ownership issues in the regulation of autologous cells.
    Sipp D
    Regen Med; 2017 Oct; 12(7):827-838. PubMed ID: 29115180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Our Fat Future: Translating Adipose Stem Cell Therapy.
    Nordberg RC; Loboa EG
    Stem Cells Transl Med; 2015 Sep; 4(9):974-9. PubMed ID: 26185256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions.
    Turner L
    Cell Stem Cell; 2021 Nov; 28(11):1891-1895. PubMed ID: 34739831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns.
    Snyder J; Turner L
    Regen Med; 2018 Jun; 13(4):375-384. PubMed ID: 29985757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.